HALOG® SOLUTION relieves itch
without causing irritation or burning and stinging.1-6
Halog® Solution is free of common irritating ingredients1,2,6
- No alcohol
- No propylene glycol
- No sodium lauryl sulfate
- No parabens
- No fragrances
Suitable for scalp and hair-bearing areas5
Avoids damaging hair1,7
Undetectable after application5
proven results for scalp psoriasis in as little as 2 weeks5
In a clinical study, 81% of patients showed improvement in their scalp psoriasis after using HALOG® Solution for two weeks.
Patient Safety: 0% of patients experienced side effects related to HALOG® Solution in this study.
HALOG® Solution CAN BE USED SAFELY ON PATIENTS OF ALL AGES1:
— with no limits on weekly dose
— on large body surface areas
The active ingredient in HALOG® Solution is halcinonide, 0.1%, the same as HALOG® Cream and HALOG® Ointment.
Apply HALOG® Solution to the affected area 2 to 3 times daily.1
Storing HALOG® Solution
HALOG® Solution should be stored at room temperature; avoid freezing and temperatures above 104°F.1
References: 1. HALOG® Solution [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2019. 2. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology. 2nd ed. NY: Springer-Verlag Berlin Heidelberg; 2000. 3. Sun Pharmaceutical Industries, Inc. Data on File. 2020 4. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009;79(2):135–140. 5. Lepaw MI. Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis. 1978;21(4):571-573. 6. Scheman A. Adverse reactions to cosmetic ingredients. Dermatol Clin. 2000;18(4):685-698. 7. Cline A, Uwakwe LN, McMichael AJ. No sulfates, no parabens, and the “no-poo” method: a new patient perspective on common shampoo ingredients. Cutis. 2018;101(1):22-26.
INDICATIONS AND USAGE
HALOG® Solution (Halcinonide Topical Solution, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
IMPORTANT SAFETY INFORMATION
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Application to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique.
Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Use in Specific Populations
Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Caution should be exercised when topical corticosteroids are administered to a nursing woman.
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Please see Full Prescribing Information of respective products.
If you experience any Adverse Events you are encouraged to report them to the Drug Safety Department at 1-800-406-7984 or email Drug.Safety@ranbaxy.com. You can also report to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.